Progress and controversies in the treatment of pediatric acute myelogenous leukemia

Current Opinion in Hematology

Volumn 9, Issue 4, 2002, Pages 353-360

  Arceci, Robert J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER REGRESSION; CHILDHOOD CANCER; DOSE RESPONSE; DOSE TIME EFFECT RELATION; HUMAN; MORBIDITY; MORTALITY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIAL; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REMISSION; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMAN; LEUKEMIA, MYELOCYTIC, ACUTE; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; HUMANS;

EID: 0036015001     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200207000-00014     Document Type: Review

References (35)

1. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
2. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
3. Acute myelogenous leukemia
4. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: A report from the Children's Cancer Group
5. A phase III study of intensive cytarabine (Ara-C) induction followed by cyclosporine (CSA) modulation of drug resistance in de novo pediatric AML: POG 9421
6. Marked improvements in outcome with chemotherapy alone in pediatric acute myeloid leukemia: Results of the United Kingdom Medical Research Council's 10th AML Trial
7. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: Results of study acute myeloid leukemia-Berlin-Frankfurt-Munster 93
8. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: A Pediatric Oncology Group study
9. Principal results of the Medical Research Council's 8th Acute Myeloid Leukaemia Trial
10. Treatment results of three consecutive German childhood AML trials: BFM-78, -83, and -87
11. Prolonged unmaintained remission after intensive consolidation therapy in adult acute nonlymphocytic leukemia
12. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: The ECOG experience
13. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification
14. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission
15. Treatment of newly diagnosed children and adolescents with acute myeloid leukemia: A Children's Cancer Group study
16. All-trans retinoic acid and low-dose chemotherapy for acute promyelocytic leukaemia
17. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines
18. Therapeutic vaccination for cancer
19. Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: A matter of controversies
20. A comparison of allogeneic bone marrow transplantation (BMT), autologous BMT, and chemotherapy in pediatric acute myeloid leukemia
21. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial
22. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry
23. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
24. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
25. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia
26. Can multidrug resistance mechanisms be modified?
27. Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia
28. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
29. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies
30. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor
31. C-kit mutations in core binding factor leukemias
32. Activating mutations of c-Kit at codon 816 confer drug resistance in human leukemia cells
33. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells
34. Targeted therapies for high-risk acute myeloid leukemia
35. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute myeloid leukemia